查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2023-2030年全球动脉粥样硬化药物市场规模研究与预测，按阶段、按诊断、按治疗、按给药途径、按终端用户、按分销渠道和区域分析。
市场调查报告书
商品编码
1290509

2023-2030年全球动脉粥样硬化药物市场规模研究与预测，按阶段、按诊断、按治疗、按给药途径、按终端用户、按分销渠道和区域分析。

Global Atherosclerosis drugs Market Size study & Forecast, by Stages, by Diagnosis, by Treatment, by Route of Administration, by End-Users, by Distribution Channel and Regional Analysis, 2023-2030
出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3个工作天内

价格

2022年全球动脉粥样硬化药物市场价值约为27亿美元，预计在2023-2030年的预测期内将以超过6.16%的健康增长率增长。动脉粥样硬化药物是用于治疗动脉粥样硬化和相关心血管疾病（如心脏病发作、中风和外周血管疾病）的一类治疗药物。这种市场增长归因于患者大量消费降胆固醇药物以减少或避免动脉阻塞。越来越快节奏的生活方式使普通人平时的饮食中的基本营养素消耗殆尽，增加了动脉粥样硬化的风险，尽管年龄组和动脉粥样硬化市场的增长率是医疗支出的上升，这有助于改善其基础设施。医疗保健部门的研究和开发导致了全球有效的动脉粥样硬化药物的生产。

据预测，动脉粥样硬化的风险增加，肥胖和高胆固醇的流行率增加，将促进市场的增长率。根据世界卫生组织（WHO）2020年的估计，有4000万五岁以下的儿童超重或肥胖。高脂肪和高糖食物消费的增加，以及许多工作对体力要求的降低所带来的身体不移动的增加，交通方式的改变和城市化的发展，都是导致人们胆固醇高的因素，推动了市场的快速扩张。此外，研究和开发活动数量的增加也推动了市场的增长，电子商务和医疗保健部门的整合将通过网上药店为动脉粥样硬化药物市场的公司带来可观的销售潜力。然而，药物的副作用和非专利产品的可用性是预计在预测期间限制市场增长的因素。

全球动脉粥样硬化药物市场研究考虑的主要地区包括亚太、北美、欧洲、拉美和中东及非洲。北美在2022年主导市场，占有最大的市场份额，因为该地区动脉粥样硬化的频率增加和治疗的技术改进。此外，医疗支出的增加和重要的关键参与者的存在将推动该地区的市场发展速度。根据2022年7月更新的国家慢性病预防和健康促进中心的心脏病和中风预防部门，在美国每34秒就有一人死于心血管疾病。在预测期内，亚太地区预计将大幅增长，因为该地区的老年人口不断增加，可支配收入水平不断提高。此外，医疗部门基础设施的扩张和政府的不断努力将加速该地区的市场扩张。

本报告中包括的主要市场参与者有

  • F.Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • 梯瓦制药工业有限公司
  • Sanofi S.A.
  • 辉瑞公司
  • GlaxoSmithKline plc
  • 诺华制药公司
  • 默克公司
  • 艾尔建公司（Allergan Plc
  • 阿斯利康

市场的最新发展：

  • 2022年9月，诺和诺德与微软达成了新的战略合作，通过使用大数据和人工智能（AI）加速药物研发。该团队将采用人工智能来构建模型，以预测一个人获得动脉粥样硬化或动脉斑块发展的风险。研究人员还将寻找新的动脉硬化目标和指标。
  • 2022年8月，阿斯利康和默克（在美国和加拿大以外称为MSD）宣布，欧盟委员会（EC）已批准LYNPARZA作为单一疗法或与内分泌疗法联合，用于辅助治疗曾接受新辅助或辅助化疗的种系BRCA1/2突变（gBRCAm）和HER2阴性高风险早期乳腺癌的成年患者。

全球动脉硬化药物市场报告范围：

  • 历史数据：2020 - 2021
  • 估计的基准年：2022年
  • 预测期：2023-2030年
  • 报告覆盖面：收入预测，公司排名，竞争格局，增长因素，和趋势
  • 涵盖的细分市场：分期、诊断、治疗、给药途径、终端用户、分销渠道、地区
  • 区域范围：北美洲；欧洲；亚太地区；拉丁美洲；中东和非洲
  • 定制范围：购买后可免费定制报告（相当于8个分析员的工作时间）。增加或改变国家、区域和部门范围*。
  • 本研究的目的是确定近年来不同细分市场和国家的市场规模，并对未来几年的价值进行预测。该报告旨在将研究涉及的国家内的行业的质量和数量方面都纳入其中。

该报告还提供了关于关键方面的详细信息，如驱动因素和挑战，这将确定市场的未来增长。此外，它还纳入了微观市场的潜在机会，供利益相关者投资，并详细分析了竞争格局和主要参与者的产品。.

目录

第一章：执行摘要

  • 市场简介
  • 2020-2030年全球和细分市场的估计和预测
    • 2020-2030年，动脉粥样硬化药物市场，按地区划分
    • 动脉粥样硬化药物市场，按阶段划分，2020-2030年
    • 2020-2030年，动脉粥样硬化药物市场，按诊断方法划分
    • 2020-2030年，动脉粥样硬化药物市场，按治疗方法划分
    • 2020-2030年，动脉粥样硬化药物市场，按给药途径划分
    • 2020-2030年，动脉粥样硬化药物市场，按终端用户划分
    • 2020-2030年动脉粥样硬化药物市场，按分销渠道划分
  • 主要趋势
  • 估算方法
  • 研究假设

第二章：全球动脉粥样硬化药物市场的定义和范围

  • 本研究的目的
  • 市场定义和范围
    • 行业演变
    • 研究的范围
  • 研究考虑的年份
  • 货币转换率

第三章：全球动脉粥样硬化药物市场动态

  • 动脉硬化药物市场影响分析（2020-2030年）
    • 市场驱动力
      • 对医疗基础设施的投资不断增加
      • 不断增长的老年人口
    • 市场挑战
      • 成本高，诊断率低
      • 药物的副作用
    • 市场机会
      • 研究和开发活动的数量增加
      • 政府倡议对提高医疗服务和基础设施的标准至关重要

第四章：全球动脉粥样硬化药物市场：行业分析

  • 波特的5力模型
    • 供应商的议价能力
    • 买方的讨价还价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 竞争性的竞争
  • 波特五力影响分析
  • PEST分析
    • 政治
    • 经济
    • 社会
    • 技术
    • 环境
    • 法律
  • 最佳投资机会
  • 最佳策略
  • COVID-19影响分析
  • 颠覆性趋势
  • 行业专家的观点
  • 分析师建议与结论

第五章：全球动脉硬化药物市场，按阶段划分

  • 市场简介
  • 全球动脉粥样硬化药物市场，按阶段、性能-潜力分析
  • 2020-2030年全球动脉粥样硬化药物市场按阶段的估计和预测
  • 动脉粥样硬化药物市场，細項分析
    • 内皮损伤和免疫反应
    • 脂肪条纹
    • 斑块生长
    • 斑块破裂

第六章：全球动脉粥样硬化药物市场，按诊断分类

  • 市场简介
  • 全球动脉粥样硬化药物市场，按诊断，性能 - 潜力分析
  • 2020-2030年全球动脉粥样硬化药物市场按诊断的估计和预测
  • 动脉粥样硬化药物市场，次级細項分析
    • 踝臂指数
    • 多普勒超声检查
    • 超声心动图
    • 心电图
    • 血液检查
    • 其他检查

第7章 ：全球动脉粥样硬化药物市场，按治疗方法分类

  • 市场简介
  • 全球动脉粥样硬化药物市场，按治疗方法，性能-潜力分析
  • 2020-2030年全球动脉粥样硬化药物市场按治疗方法估计和预测的情况
  • 动脉粥样硬化症药物市场，細項分析
    • 药物治疗
    • 手术治疗
    • 其他疗法

第八章：全球动脉粥样硬化药物市场，按给药途径分类

  • 市场简介
  • 按给药途径分類的全球动脉粥样硬化药物市场，表现 - 潜力分析
  • 2020-2030年全球动脉粥样硬化药物市场按给药途径估计和预测的情况
  • 动脉粥样硬化症药物市场，細項分析
    • 口服
    • 肠外
    • 其他途径

第九章：全球动脉粥样硬化药物市场，按终端用户分类

  • 市场简介
  • 按终端用户分類的全球动脉粥样硬化药物市场，性能-潜力分析
  • 2020-2030年全球动脉粥样硬化药物市场按终端用户的估计和预测
  • 动脉粥样硬化症药物市场，細項分析
    • 医院
    • 专业诊所
    • 家庭护理
    • 其他

第十章：全球动脉粥样硬化药物市场，按分销渠道划分

  • 市场简介
  • 按分销渠道分類的全球动脉粥样硬化药物市场，表现 - 潜力分析
  • 2020-2030年全球动脉粥样硬化药物市场按分销渠道的估计和预测
  • 动脉粥样硬化症药物市场，細項分析
    • 医院药房
    • 零售药店
    • 网上药店
    • 其他渠道

第十一章 ：全球动脉硬化药物市场，区域分析

  • 最领先的国家
  • 新兴国家
  • 动脉粥样硬化症药物市场，区域市场简介
  • 北美洲
    • 美国
      • 2020-2030年各阶段细分估计和预测
      • 2020-2030年，诊断的细分估计和预测
      • 2020-2030年，治疗细分的估计和预测
      • 2020-2030年给药途径细分的估计和预测
      • 2020-2030年终端用户分类估计和预测
      • 2020-2030年分销渠道细分的估计和预测
    • 加拿大
  • 欧洲动脉粥样硬化药物市场简介
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 意大利
    • 欧洲其他地区
  • 亚太地区动脉粥样硬化药物市场简介
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 韩国
    • 亚太其他地区
  • 拉丁美洲动脉粥样硬化药物市场简介
    • 巴西
    • 墨西哥
  • 中东和非洲
    • 沙特
    • 南非
    • 中东和非洲其他地区

第十二章 ：竞争情报

  • 主要公司SWOT分析
    • 公司1
    • 公司二
    • 公司3
  • 顶级市场战略
  • 公司简介
    • F. Hoffmann-La Roche Ltd.
      • 关键信息
      • 概况
      • 财务（取决于数据的可用性）
      • 产品摘要
      • 近期发展情况
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi India
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Merck & Co
    • Allergan India Pvt Ltd.
    • AstraZeneca

第十三章 ：研究过程

  • 研究过程
    • 资料探勘
    • 分析
    • 市场评估
    • 验证
    • 出版
  • 研究属性
  • 研究假设

Global Atherosclerosis drugs Market is valued approximately at USD 2.7 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6.16% over the forecast period 2023-2030. Atherosclerosis drugs is a therapeutic category of medications used for the treatment of atherosclerosis and related cardiovascular diseases such as heart attacks, strokes, and peripheral vascular disease. This market growth is attributed to the high consumption of cholesterol-lowering drugs by patients to reduce or avoid blockages in arteries. The increasingly fast-paced lifestyle has depleted the ordinary person's usual diet of essential nutrients that increases the risk of atherosclerosis, despite the age group and the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. The research and development in the healthcare sector have led to the production of effective atherosclerosis drugs globally.

Increasing the risk of atherosclerosis, the increased prevalence of obesity and high cholesterol is predicted to boost the market's growth rate. According to estimates from the World Health Organisation (WHO) in 2020, 40 million children under the age of five were overweight or obese. Increased consumption of food high in fat and sugar as well as an increase in physical immobility brought on by the fact that many jobs are becoming less physically demanding, changing transportation options and growing urbanization are the factors that contributes to high cholesterol rates in people that are driving the market's rapid expansion. Moreover, the market's growth is fueled by an increase in the number of research and development activities also the integration of e-Commerce and the healthcare sector will generate considerable sales potential through online pharmacies for companies in the atherosclerosis medicines market. However, Side effects of drugs and the availability of generic products are the factors expected to restrain the market growth during the forecast period.

The key regions considered for the Global Atherosclerosis drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 holding the largest market share owing to the increased frequency of atherosclerosis and technical improvement in the treatment in this region. Furthermore, increased healthcare expenditure and the presence of significant key players would drive the market development rate in this area. According to the National Centre for Chronic Disease Prevention and Health Promotion's Division for Heart Disease and Stroke Prevention, which was updated in July 2022, one person dies from cardiovascular disease every 34 seconds in the United States. Asia Pacific is expected to grow significantly during the forecast period, owing to the growing elderly population in this area and the rising level of disposable income. Additionally, the expansion of the healthcare sector's infrastructure and growing government efforts will accelerate the market's expansion in this area.

Major market player included in this report are:

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co
  • Allergan Plc
  • AstraZeneca

Recent Developments in the Market:

  • In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development. The researchers will also look for new atherosclerosis targets and indicators.
  • In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

Global Atherosclerosis drugs Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Stages, Diagnosis, Treatment, Route of Administration, End-Users, Distribution Channel, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
  • The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Stages:

  • Endothelial Damage and Immune Response
  • Fatty Streak
  • Plaque Growth
  • Plaque Rupture

By Diagnosis:

  • Ankle-brachial Index
  • Doppler Ultrasound
  • Echocardiogram
  • Electrocardiogram
  • Blood Tests
  • Others

By Treatment:

  • Medication
  • Surgery
  • Others

By Route of Administration:

  • Oral,
  • Parenteral
  • Others

By End-Users:

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Atherosclerosis drugs Market, by region, 2020-2030 (USD Billion)
    • 1.2.2. Atherosclerosis drugs Market, by Stages, 2020-2030 (USD Billion)
    • 1.2.3. Atherosclerosis drugs Market, by Diagnosis, 2020-2030 (USD Billion)
    • 1.2.4. Atherosclerosis drugs Market, by Treatment, 2020-2030 (USD Billion)
    • 1.2.5. Atherosclerosis drugs Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.6. Atherosclerosis drugs Market, by End-User, 2020-2030 (USD Billion)
    • 1.2.7. Atherosclerosis drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Atherosclerosis drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Atherosclerosis drugs Market Dynamics

  • 3.1. Atherosclerosis drugs Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing investment in healthcare infrastructure
      • 3.1.1.2. Growing Geriatric Population
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost and low diagnostic rates
      • 3.1.2.2. Side effects of drugs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in the number of research and development activities
      • 3.1.3.2. Government initiatives have been essential in raising the standard of healthcare services and infrastructure

Chapter 4. Global Atherosclerosis drugs Market: Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economic
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Atherosclerosis drugs Market, by Stages

  • 5.1. Market Snapshot
  • 5.2. Global Atherosclerosis drugs Market by Stages, Performance - Potential Analysis
  • 5.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Stages 2020-2030 (USD Billion)
  • 5.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 5.4.1. Endothelial Damage and Immune Response
    • 5.4.2. Fatty Streak
    • 5.4.3. Plaque Growth
    • 5.4.4. Plaque Rupture

Chapter 6. Global Atherosclerosis drugs Market, by Diagnosis

  • 6.1. Market Snapshot
  • 6.2. Global Atherosclerosis drugs Market by Diagnosis, Performance - Potential Analysis
  • 6.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Diagnosis 2020-2030 (USD Billion)
  • 6.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 6.4.1. Ankle-brachial Index
    • 6.4.2. Doppler Ultrasound
    • 6.4.3. Echocardiogram
    • 6.4.4. Electrocardiogram
    • 6.4.5. Blood Tests
    • 6.4.6. Others

Chapter 7. Global Atherosclerosis drugs Market, by Treatment

  • 7.1. Market Snapshot
  • 7.2. Global Atherosclerosis drugs Market by Treatment, Performance - Potential Analysis
  • 7.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
  • 7.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 7.4.1. Medication
    • 7.4.2. Surgery
    • 7.4.3. Others

Chapter 8. Global Atherosclerosis drugs Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Atherosclerosis drugs Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 8.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 8.4.1. Oral
    • 8.4.2. Parenteral
    • 8.4.3. Others

Chapter 9. Global Atherosclerosis drugs Market, by End-User

  • 9.1. Market Snapshot
  • 9.2. Global Atherosclerosis drugs Market by End-User, Performance - Potential Analysis
  • 9.3. Global Atherosclerosis drugs Market Estimates & Forecasts by End-User2020-2030 (USD Billion)
  • 9.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
    • 9.4.3. Homecare
    • 9.4.4. Others

Chapter 10. Global Atherosclerosis drugs Market, by Distribution Channel

  • 10.1. Market Snapshot
  • 10.2. Global Atherosclerosis drugs Market by Distribution Channel, Performance - Potential Analysis
  • 10.3. Global Atherosclerosis drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 10.4. Atherosclerosis drugs Market, Sub Segment Analysis
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Pharmacy
    • 10.4.4. Others

Chapter 11. Global Atherosclerosis drugs Market, Regional Analysis

  • 11.1. Top Leading Countries
  • 11.2. Top Emerging Countries
  • 11.3. Atherosclerosis drugs Market, Regional Market Snapshot
  • 11.4. North America Atherosclerosis Drugs Market
    • 11.4.1. U.S. Atherosclerosis drugs Market
      • 11.4.1.1. Stages breakdown estimates & forecasts, 2020-2030
      • 11.4.1.2. Diagnosis breakdown estimates & forecasts, 2020-2030
      • 11.4.1.3. Treatment breakdown estimates & forecasts, 2020-2030
      • 11.4.1.4. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 11.4.1.5. End-User breakdown estimates & forecasts, 2020-2030
      • 11.4.1.6. Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 11.4.2. Canada Atherosclerosis drugs Market
  • 11.5. Europe Atherosclerosis drugs Market Snapshot
    • 11.5.1. U.K. Atherosclerosis drugs Market
    • 11.5.2. Germany Atherosclerosis drugs Market
    • 11.5.3. France Atherosclerosis drugs Market
    • 11.5.4. Spain Atherosclerosis drugs Market
    • 11.5.5. Italy Atherosclerosis drugs Market
    • 11.5.6. Rest of Europe Atherosclerosis drugs Market
  • 11.6. Asia-Pacific Atherosclerosis drugs Market Snapshot
    • 11.6.1. China Atherosclerosis drugs Market
    • 11.6.2. India Atherosclerosis drugs Market
    • 11.6.3. Japan Atherosclerosis drugs Market
    • 11.6.4. Australia Atherosclerosis drugs Market
    • 11.6.5. South Korea Atherosclerosis drugs Market
    • 11.6.6. Rest of Asia Pacific Atherosclerosis Drugs Market
  • 11.7. Latin America Atherosclerosis drugs Market Snapshot
    • 11.7.1. Brazil Atherosclerosis drugs Market
    • 11.7.2. Mexico Atherosclerosis drugs Market
  • 11.8. Middle East & Africa Atherosclerosis drugs Market
    • 11.8.1. Saudi Arabia Atherosclerosis drugs Market
    • 11.8.2. South Africa Atherosclerosis drugs Market
    • 11.8.3. Rest of Middle East & Africa Atherosclerosis drugs Market

Chapter 12. Competitive Intelligence

  • 12.1. Key Company SWOT Analysis
    • 12.1.1. Company 1
    • 12.1.2. Company 2
    • 12.1.3. Company 3
  • 12.2. Top Market Strategies
  • 12.3. Company Profiles
    • 12.3.1. F. Hoffmann-La Roche Ltd.
      • 12.3.1.1. Key Information
      • 12.3.1.2. Overview
      • 12.3.1.3. Financial (Subject to Data Availability)
      • 12.3.1.4. Product Summary
      • 12.3.1.5. Recent Developments
    • 12.3.2. Mylan N.V.
    • 12.3.3. Teva Pharmaceutical Industries Ltd.
    • 12.3.4. Sanofi India
    • 12.3.5. Pfizer Inc.
    • 12.3.6. GlaxoSmithKline plc
    • 12.3.7. Novartis AG
    • 12.3.8. Merck & Co
    • 12.3.9. Allergan India Pvt Ltd.
    • 12.3.10. AstraZeneca

Chapter 13. Research Process

  • 13.1. Research Process
    • 13.1.1. Data Mining
    • 13.1.2. Analysis
    • 13.1.3. Market Estimation
    • 13.1.4. Validation
    • 13.1.5. Publishing
  • 13.2. Research Attributes
  • 13.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Atherosclerosis drugs Market, report scope
  • TABLE 2. Global Atherosclerosis drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Atherosclerosis drugs Market estimates & forecasts by Stages 2020-2030 (USD Billion)
  • TABLE 4. Global Atherosclerosis drugs Market estimates & forecasts by Diagnosis 2020-2030 (USD Billion)
  • TABLE 5. Global Atherosclerosis drugs Market estimates & forecasts by Treatment 2020-2030 (USD Billion)
  • TABLE 6. Global Atherosclerosis drugs Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
  • TABLE 7. Global Atherosclerosis drugs Market estimates & forecasts by End-User 2020-2030 (USD Billion)
  • TABLE 8. Global Atherosclerosis drugs Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 9. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. Global Atherosclerosis drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Global Atherosclerosis drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 19. U.S. Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. U.S. Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. U.S. Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. Canada Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. Canada Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. Canada Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. UK Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. UK Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. UK Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. Germany Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. Germany Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. Germany Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. France Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. France Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. France Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Italy Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Italy Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Italy Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. Spain Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. Spain Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. Spain Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. RoE Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. RoE Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. RoE Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. China Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. China Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. China Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. India Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. India Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. India Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. Japan Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. Japan Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. Japan Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. South Korea Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. South Korea Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. South Korea Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. Australia Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. Australia Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. Australia Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. RoAPAC Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. RoAPAC Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. RoAPAC Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Brazil Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Brazil Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Brazil Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. Mexico Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. Mexico Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. Mexico Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoLA Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. RoLA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoLA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. Saudi Arabia Atherosclerosis drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 71. South Africa Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 72. RoMEA Atherosclerosis drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 73. List of secondary sources, used in the study of global Atherosclerosis drugs Market
  • TABLE 74. List of primary sources, used in the study of global Atherosclerosis drugs Market
  • TABLE 75. Years considered for the study
  • TABLE 76. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

  • FIG 1. Global Atherosclerosis drugs Market, research methodology
  • FIG 2. Global Atherosclerosis drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Atherosclerosis drugs Market, key trends 2022
  • FIG 5. Global Atherosclerosis drugs Market, growth prospects 2023-2030
  • FIG 6. Global Atherosclerosis drugs Market, porters 5 force model
  • FIG 7. Global Atherosclerosis drugs Market, pest analysis
  • FIG 8. Global Atherosclerosis drugs Market, value chain analysis
  • FIG 9. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Atherosclerosis drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Atherosclerosis drugs Market, regional snapshot 2020 & 2030
  • FIG 15. North America Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Atherosclerosis drugs Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Atherosclerosis drugs Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable